Loading, please wait...
RESIDENT SEMINAR SCHEDULE
Tuesday, October 10, 2023
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
EVALUATION - CLICK HERE *must be completed for each presentation in order to receive CPE credit - will need your NABP ID & 4 digit DOB (MMDD) |
ADVANCE REGISTRATION & PARKING FORM | UHSP CAMPUS MAP & DIRECTIONS |
Please join us for the first Resident Seminar session of the 2023-24 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in classrooms in the Academic & Research Building (ARB) on the third floor as well as virtually via Teams.
Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned for this Resident Seminar is 2.25 contact hours. Participants must complete an evaluation (see link above) to receive credit.
|
|
||||
|
SESSION 1
1:00 – 1:45
|
Aminoglycoside Breakpoint Changes
Lauren Russell, PharmD
|
Second Line Therapy in Statin Intolerance
Logan Kesler, PharmD
|
Role of phenobarbital for alcohol withdrawal
Lizzy Williams, PharmD
|
GLP-1 agonists for weight loss
Nicole Gasparovic, PharmD
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40
|
New options for the management of carbapenem-resistant Acinetobacter: is sulbactam-durlobactam going to change the landscape?
Blake Remensnyder, PharmD
|
Strategies to Overcome Diuretic Resistance in Acute Heart Failure
Shelby Go, PharmD
|
Early enteral vs parenteral nutrition in critically ill patients
Jessica Hall, PharmD
|
Antidepressants in bipolar disorder
Allison Wadlow, PharmD
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:35
|
|
Sotagliflozin (Inpefa) for the treatment of heart failure
Adna Tokmic, PharmD
|
Xylazine and opioid overdose reversal
Madeline Gemoules, PharmD
|
Antithrombotic Recommendations for Patients Post-Cardiac Valve Replacement
Austin Pennell, PharmD
|
REGISTRATION & PARKING: FREE, but required in advance if parking is needed: click here to access the Resident Seminar Registration & Parking Form.
If you plan to attend in person and park in the UHSP Main Garage (4531 Nash Way, St. Louis, MO 63110), this form must be submitted by no later than October 6. If you plan to attend virtually, you do not need to register - join via the Microsoft Teams links above.
HANDOUTS: Participants attending in-person will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the conversation feature within Teams.
ATTENDANCE & EVALUATION: Attendance will be collected for both in-person and live participants. In order to receive CPE credit, partipants must complete the evaluation linked above and enter a unique claim code that will be provided by the presenter immediately following after each presemtation. An evaluation must be completed for EACH presentation attended (3 maximum) in order to receive full credit. The evaluation link will remain upon for 1 week after the session; after that time, evaluations will close and CPE credit may no longer be claimed. To receive CPE credit, participants must enter their full and accurate NABP ID number and 4-digit date of birth (MMDD) when completing the evaluation. CPE Credit will be submitted to CPE Monitor for participants by no later than 2 weeks after the session.To best comply with ACPE's CPE credit reporting policy, CPE credit cannot be awarded or corrected if more than 60 days have passed from the event.
ATTENDANCE & EVALUATION: Attendance will be collected for both in-person and live participants. In order to receive CPE credit, partipants must complete the evaluation linked above and enter a unique claim code that will be provided by the presenter immediately following after each presemtation. An evaluation must be completed for EACH presentation attended (3 maximum) in order to receive full credit. The evaluation link will remain upon for 1 week after the session; after that time, evaluations will close and CPE credit may no longer be claimed. To receive CPE credit, participants must enter their full and accurate NABP ID number and 4-digit date of birth (MMDD) when completing the evaluation. CPE Credit will be submitted to CPE Monitor for participants by no later than 2 weeks after the session.To best comply with ACPE's CPE credit reporting policy, CPE credit cannot be awarded or corrected if more than 60 days have passed from the event.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you will require accommodations, please notify ce@uhsp.edu.
Date: Oct 10, 2023 01:00 PM - 03:35 PM
Fee
$0.00
CE Hours
8.25
Activity Type
- Knowledge
Support/Credits
In 2023, the Clinical and Laboratory Standards Institute published breakpoint changes for gentamicin, tobramycin, and amikacin for both Pseudomonas aeruginosa and Enterobacterales. These changes have a clinical impact on selection of aminoglycoside and dosing. This presentation will explain how breakpoints are determined, provide the rationale for the aminoglycoside breakpoint changes, critique the data supporting the changes, and offer implementation suggestions for hospitals.
Objectives
- Describe the process of updating breakpoints including organizations involved and data that is reviewed?
- Describe the data behind the aminoglycoside breakpoint changes for Enterobacterales and Pseudomonas aeruginosa
- Summarize updates to the Clinical and Laboratory Standards Institute (CLSI) M100 on aminoglycoside breakpoints for Enterobacterales and Pseudomonas aeruginosa?
Speaker(s)/Author(s)
|
Lauren Russell, PharmD |
Activity Number
0033-0000-23-013-L01-P
Date:
10/10/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304
Xylazine is an alpha-2 agonist that is emerging as a prevalent adulterant in combination with current drugs of abuse, including opioids. These combinations can cause significant issues related to overdose and other complications. The goal of this presentation is to compare the pharmacology of alpha-2 adrenergic receptor agonists to opioid antagonists as it applies to mechanism of overdose and reversal management. This presentation will review initial identification and management of patients with suspected xylazine-adulterated illicit opioid overdose and review appropriate supportive care strategies. Participants will also learn how to identify and manage complications that are unique to xylazine, including xylazine related wounds and secondary bacterial infections.
Objectives
- Compare the pharmacology of opioid agonists to alpha-2 adrenergic receptor agonists as it applies to overdose and reversal management
- Identify complications of xylazine use and appropriate management
- Describe initial identification and management of patients with suspected xylazine-adulterated illicit opioid overdose
Speaker(s)/Author(s)
|
Madeline Gemoules, PharmD |
Activity Number
0033-0000-23-016-L01-P
Date:
10/10/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 354
This CE activity seeks to provide a clinical approach to management of acute heart failure complicated by diuretic
resistance. This presentation will evaluate available literature supporting the use of various strategies to overcome
diuretic resistance, in particular sequential nephron blockade.
resistance. This presentation will evaluate available literature supporting the use of various strategies to overcome
diuretic resistance, in particular sequential nephron blockade.
Objectives
- Describe the initial diuretic approach for acute heart failure.
- Identify the proposed mechanisms of diuretic resistance.
- Outline strategies to overcome diuretic resistance and utilize supporting literature to develop a step-wise approach to overcome diuretic resistance.
Speaker(s)/Author(s)
|
Shelby Go, PharmD |
Activity Number
0033-0000-23-018-L01-P
Date:
10/10/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
This presentation will begin by introducing background about obesity including epidemiology and a
brief history of the management of obesity and available treatment options. The most current clinical
practice guidelines will be introduced and I will transition to discussing GLP-1 agonists and their
utility in the treatment of weight loss. I will present two pieces of primary literature about weight regain
seen upon discontinuation and also discuss safety concerns and optimal duration of therapy. I will
conclude with final thoughts, future considerations, and assessment questions. The overall goal for
the audience is to better understand the data surrounding GLP-1 agonists for weight loss so
they can apply their knowledge to clinical practice.
brief history of the management of obesity and available treatment options. The most current clinical
practice guidelines will be introduced and I will transition to discussing GLP-1 agonists and their
utility in the treatment of weight loss. I will present two pieces of primary literature about weight regain
seen upon discontinuation and also discuss safety concerns and optimal duration of therapy. I will
conclude with final thoughts, future considerations, and assessment questions. The overall goal for
the audience is to better understand the data surrounding GLP-1 agonists for weight loss so
they can apply their knowledge to clinical practice.
Objectives
- Describe the mechanism of action of GLP-1 agonists as it relates to weight loss.
- Identify patients who are eligible for GLP-1 therapy based on FDA approval criteria.
- Explain risks and benefits associated with using GLP-1 agonists.
Speaker(s)/Author(s)
|
Nicole Gasparovic, PharmD |
Activity Number
0033-0000-23-017-L01-P
Date:
10/10/23
Time:
04:00 PM - 05:00 PM
CE Hours
0.75
Location
ARB 355
Bipolar disorder is categorized into two distinct symptom groups - mania/hypomania and depression. When targeting the depressive symptoms, an initial reaction may be to treat these symptoms with medications which haven demonstrated efficacy in unipolar depression – antidepressants The FDA has even approved an antipsychotic-antidepressant combination medication with the indication of bipolar depression. However, data is conflicting on the safety of providing patients with bipolar disorder an antidepressant. The use of antidepressants in bipolar disorder is controversial due to data suggesting possible affective switch to mania, induction of rapid cycling, and overall lack of efficacy.
Objectives
- Identify signs and symptoms of bipolar disorder
- Summarize guideline recommendations in treating Bipolar disorder
- Describe the concerns associated with antidepressant use in bipolar disorder
Speaker(s)/Author(s)
|
Allison Wadlow, PharmD |
Activity Number
0033-0000-23-010-L01-P
Date:
10/10/23
Time:
01:45 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355
Critically ill patients have higher nutrition requirements due to being in a catabolic stress state with systemic inflammation and multiple organ dysfunction. Therefore, nutritional support is an important component of the care of these patients with a goal of improving clinical outcomes. Nutrition can be provided via the enteral or parenteral route. There are risks associated with each of these approaches, however, previous literature has shown many theoretic benefits of enteral nutrition including preserving gut structure and function. Historically, nutrition guidelines have supported the use of early enteral nutrition over parenteral nutrition due to these benefits as well as the risk of infection associated with parenteral nutrition. In 2022, the American Society for Parenteral and Enteral Nutrition (ASPEN) published an update to their 2016 guidelines. The updated guidelines provided a strong recommendation for the use of either early enteral or parenteral nutrition due to a lack of significant differences in clinical outcomes between the two routes. This recommendation is based on the findings from two randomized controlled trials comparing early enteral and parenteral nutrition. This presentation will analyze these two studies as well as a cost-effective analysis to determine the ideal route of administration of nutritional support in critically ill patients.
Objectives
- Identify benefits of providing enteral nutrition
- Summarize key guideline recommendations from ESICM, ESPEN, and ASPEN
- Develop a nutrition regimen based on patient specific factors
Speaker(s)/Author(s)
|
Jessica Hall, PharmD |
Activity Number
0033-0000-23-012-L01-P
Date:
10/10/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354
This activity will discuss alcohol withdrawal syndrome, 3 pertinent studies over effectiveness, dosing and a meta-analysis. The overall goal for the audience is to increase knowledge about the use of phenobarbital and discuss different dosing regimens.
Objectives
- Identify signs, symptoms, and severity of alcohol withdrawal syndrome.
- Describe the risks and benefits of phenobarbital.
- Discuss phenobarbital’s place in therapy based on available literature.
Speaker(s)/Author(s)
|
Lizzy Williams, PharmD |
Activity Number
0033-0000-23-014-L01-P
Date:
10/10/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354
Heart failure (HF) remains a leading cause of morbidity and mortality globally. Pharmacological
therapy is an important component of HF management to provide symptomatic relief and reduce
morbidity and mortality. Guideline-directed medical therapy (GDMT) for HF with reduced ejection
fraction (HFrEF) and preserved ejection fraction (HFpEF) includes sodium-glucose cotransporter-2
inhibitors (SGLT2i), specifically empagliflozin (Jardiance) and dapagliflozin (Farxiga). On May 26, 2023, the
US Food and Drug Administration approved sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2
inhibitor, for the treatment of HFrEF and HFpEF. The agent was approved to reduce the risk of
cardiovascular (CV) death, hospitalization for HF and urgent HF visits in adults with HF or type 2
diabetes, chronic kidney disease or other CV risk factors. With the approval, sotagliflozin becomes
the third drug with SGLT2 inhibition to receive an indication for HF. To improve patient care, it is
essential for pharmacists to understand the clinical pearls of sotagliflozin and its' role in HF
management.
therapy is an important component of HF management to provide symptomatic relief and reduce
morbidity and mortality. Guideline-directed medical therapy (GDMT) for HF with reduced ejection
fraction (HFrEF) and preserved ejection fraction (HFpEF) includes sodium-glucose cotransporter-2
inhibitors (SGLT2i), specifically empagliflozin (Jardiance) and dapagliflozin (Farxiga). On May 26, 2023, the
US Food and Drug Administration approved sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2
inhibitor, for the treatment of HFrEF and HFpEF. The agent was approved to reduce the risk of
cardiovascular (CV) death, hospitalization for HF and urgent HF visits in adults with HF or type 2
diabetes, chronic kidney disease or other CV risk factors. With the approval, sotagliflozin becomes
the third drug with SGLT2 inhibition to receive an indication for HF. To improve patient care, it is
essential for pharmacists to understand the clinical pearls of sotagliflozin and its' role in HF
management.
Objectives
- Identify patients who may benefit from sotagliflozin therapy
- Discuss available literature regarding the safety and efficacy of sotagliflozin in heart failure
- Compare and contrast sotagliflozin to other SGLT2 inhibitors
Speaker(s)/Author(s)
|
Adna Tokmic, PharmD |
Activity Number
0033-0000-23-009-L01-P
Date:
10/10/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 305
My program will start with a brief background on types of heart valves and heart valve replacement techniques, with further information on transcatheter aortic valve implantation (TAVI). I will discuss the need for antithrombotic therapy in these patients, identify the different oral agents available (both antiplatelets and anticoagulants), and explain their mechanisms in the setting of platelet aggregation or clotting. I will then discuss guideline recommendations for antithrombotic therapy in TAVR patients and identify discrepancies or gaps of information between guidelines. I will then analyze primary literature covering the use of DOACs, vitamin-K antagonists (warfarin), and antiplatelet agents in this patient population. I will then summarize my findings, state my conclusions, and give my recommendations.
Objectives
- Identify how direct oral anticoagulants affect the coagulation cascade.
- Identify indications for long-term anticoagulation in post-transcatheter aortic valve implantation patients.
- Define guideline recommended antithrombotic therapy in the setting of transcatheter aortic valve replacement.
Speaker(s)/Author(s)
|
Austin Pennell, PharmD |
Activity Number
0033-0000-23-011-L01-P
Date:
10/10/23
Time:
02:50 PM - 03:55 PM
CE Hours
0.75
Location
ARB 355
This activity will first cover the history of CRAB leading up to the current threat faced by a highly resistant organism with limited treatment options, associated with high mortality rates. We will then review the current guidelines used in the treatment of CRAB infections, discussing scenarios where one agent may be preferred over another. While reviewing primary literature we will examine evidence for the current recommendations, combination therapy and sulbactam-durlobactam in CRAB infections. The presentation will be concluded with a case example and a summary of key points. The goal of this presentation is to familiarize the audience with the current treatment algorithm for CRAB, discuss the efficacy of combination therapy and postulate the future place in therapy for sulbactam-durlobactam.
Objectives
- Describe the role of combination therapy in the treatment of CRAB infections
- Discuss the place in therapy of cefiderocol in the treatment of infections caused by CRAB
- Postulate the role of sulbactam-durlobactam in the future treatment of CRAB
Speaker(s)/Author(s)
|
Blake Remensnyder, PharmD |
Activity Number
0033-0000-23-008-L01-P
Date:
10/10/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304
Statins are the main treatment for hypercholesterolemia and the cornerstone of atherosclerotic
cardiovascular disease (ASCVD) prevention. However, these popular medications are associated
with muscle-related symptoms causing frequent discontinuation and in turn leading to increased risk
of cardiovascular events for patients. Statin intolerance is a vague term that is defined as any
adverse event considered unacceptable by the patient and/or laboratory abnormalities. The National
Lipid Associated defines statin intolerance as the inability to tolerate at least two statins as
determined by the patient. If statins cannot be tolerated, other lipid-lowering medications can be
utilized to achieve low-density lipoprotein (LDL) goals. Proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors have proven cardiovascular benefit and have been approved for patients who are
statin intolerant. However, PCSK9 inhibitors are injectable medications associated with a high cost
which makes them less desirable to some patient populations. Despite having less LDL lowering
capability, a new cheaper oral medication, Bempedoic acid, was created to lower LDL in patients
with a statin intolerance. The goal of this presentation is to explore Bempedoic acid’s role in statin
intolerant patients.
cardiovascular disease (ASCVD) prevention. However, these popular medications are associated
with muscle-related symptoms causing frequent discontinuation and in turn leading to increased risk
of cardiovascular events for patients. Statin intolerance is a vague term that is defined as any
adverse event considered unacceptable by the patient and/or laboratory abnormalities. The National
Lipid Associated defines statin intolerance as the inability to tolerate at least two statins as
determined by the patient. If statins cannot be tolerated, other lipid-lowering medications can be
utilized to achieve low-density lipoprotein (LDL) goals. Proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors have proven cardiovascular benefit and have been approved for patients who are
statin intolerant. However, PCSK9 inhibitors are injectable medications associated with a high cost
which makes them less desirable to some patient populations. Despite having less LDL lowering
capability, a new cheaper oral medication, Bempedoic acid, was created to lower LDL in patients
with a statin intolerance. The goal of this presentation is to explore Bempedoic acid’s role in statin
intolerant patients.
Objectives
- Describe differences in the mechanisms of action for statins, ezetimibe, PCSK9 inhibitors, and Bempedoic Acid
- Identify data surrounding the use of Bempedoic Acid in statin intolerant patients
- Explain the benefits of Bempedoic Acid vs alternative therapies in patients with statin intolerance
Speaker(s)/Author(s)
|
Logan Kesler, PharmD |
Activity Number
0033-0000-23-015-L01-P
Date:
10/10/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305
